Relypsa Inc shares are down 38 percent year-to-date, while shares of ZS Pharma Inc are up 14 percent over the same period. Citi’s Yigal Nochomovitz maintained a Buy rating on both companies, with price targets of $45 for Relypsa and of $82 for ZS Pharma. The proposed indication of ZS Pharma validates the bull thesis on the hyperkalemia market and the potential of Relypsa’s Veltassa, Nochomovitz stated.